MGM -> ODSMT pt 2
I would like more educated people to comment on my conceptual understanding and plan.
For basic understanding MGM hits the MU and the DELTA receptors.
SR-17018 does NOT hit the delta receptor, only the MU, so once stabilized on a compound that does not include DELTA receptor activity the taper would be easier (much like going to 7oh prior to SR)
My understanding is that while the MU transition to ODSMT would be rough it would roughly be mitigated with norepinephrine transporter inhibition due to introducing the ODSMT
Simultaneously, I could potentially taper my DELTA receptor by using basic mitragynine extract.
1.) Switch to a weaker compound with single receptor activity
2.) mitigate DELTA receptor withdrawal with a mitragynine extract taper
3.) Introduce SR once stabilized
4.) Taper off ODSMT (to handle MU receptors) and Mitragynine (to handle delta receptors)
__________________
I am including basic pharmacology information at the bottom of this post.
MGM15→ O-DSMT → SR-17018
Conceptually, this is a more gradual change in receptor profile:
MGM-15
MOR + DOR
↓
O-DSMT
Mostly MOR
Loses most DOR activity
Adds norepinephrine transporter inhibition
↓
SR-17018
Mostly MOR
Removes the norepinephrine transporter effect
Different MOR signaling profile
In simple terms:
MGM-15 → O-DSMT removes the delta component but keeps conventional MOR agonism.
O-DSMT → SR-17018 keeps MOR engagement but changes how that receptor is activated.
Theoretically DELTA receptor tapering could be done with a mitragynine extract
——————
Pharmacology profiles
For those who do not know, MGM hits two opioid receptors, actually three, potentially.
“Mu (μ) Opioid Receptor (MOR): Agonist
Delta (δ) Opioid Receptor (DOR): Agonist
Kappa (κ) Opioid Receptor (KOR): Minimal to negligible activity
Nociceptin (NOP/ORL-1) Receptor: Unknown / not established
Serotonin Transporter (SERT): Unknown
Norepinephrinen Transporter (NET): Unknown
5-HT2A Serotonin Receptors: Unknown
α2-Adrenergic Receptors: Unknown
SR-17018
Mu (μ) Opioid Receptor (MOR): G protein-biased partial agonist
Delta (δ) Opioid Receptor (DOR): Negligible activity
Kappa (κ) Opioid Receptor (KOR): Very weak affinity; no meaningful agonist activity
Nociceptin (NOP/ORL-1) Receptor: Unknown / not established
Serotonin Transporter (SERT): No meaningful activity
Norepinephrine Transporter (NET): No meaningful activity
That means withdrawal from the DELTA receptor IS NOT COVERED.
ODSMT:
Mu (μ) Opioid Receptor (MOR): Agonist
Delta (δ) Opioid Receptor (DOR): Minimal to negligible activity
Kappa (κ) Opioid Receptor (KOR): Minimal to negligible activity
Nociceptin (NOP/ORL-1) Receptor: Unknown / not established
Serotonin Transporter (SERT): Weak inhibition (less than tramadol)
Norepinephrine Transporter (NET): Moderate inhibition
5-HT2A Serotonin Receptors: No meaningful direct activity
α2-Adrenergic Receptors: No meaningful direct agonist activity
Kratom
(plain leaf) is an interesting pharmacological profile in that it that potentially interacts with a MYRIAD of receptors
“Mu (μ) Opioid Receptor (MOR): Partial agonist
Delta (δ) Opioid Receptor (DOR): Weak agonist / minimal activity
Kappa (κ) Opioid Receptor (KOR): Antagonist or very weak partial agonist (assay-dependent)
Nociceptin (NOP/ORL-1) Receptor: Weak agonist
α2-Adrenergic Receptors: Agonist
5-HT2A Serotonin Receptors: Weak interaction
5-HT7 Serotonin Receptors: Possible weak interaction
D2 Dopamine Receptors: Weak interaction
L-type Calcium Channels: Inhibitory activity”
Mitragynine:
Mu (μ) Opioid Receptor (MOR): Partial agonist
Delta (δ) Opioid Receptor (DOR): Weak agonist / minimal activity
Kappa (κ) Opioid Receptor (KOR): Antagonist or very weak partial agonist (assay-dependent)
Nociceptin (NOP/ORL-1) Receptor: Weak agonist
Serotonin Transporter (SERT): No meaningful inhibition
Norepinephrine Transporter (NET): No meaningful inhibition
5-HT2A Serotonin Receptors: Weak interaction
α2-Adrenergic Receptors: Agonist
D2 Dopamine Receptors: Weak interaction
L-type Calcium Channels: Inhibitory activity
For a whole kratom (Mitragyna speciosa) extract, the pharmacological profile reflects the combined activity of dozens of alkaloids—not just mitragynine. Because alkaloid ratios vary by plant, extraction method, and product, this is a generalized profile:
Mu (μ) Opioid Receptor (MOR): Partial agonist (primarily via mitragynine and 7-hydroxymitragynine)
Delta (δ) Opioid Receptor (DOR): Weak agonist / minimal activity
Kappa (κ) Opioid Receptor (KOR): Antagonist or very weak partial agonist (assay-dependent)
Nociceptin (NOP/ORL-1) Receptor: Weak agonist
Serotonin Transporter (SERT): Minimal to no meaningful inhibition
Norepinephrine Transporter (NET): Minimal to weak inhibition
5-HT2A Serotonin Receptors: Weak interaction
5-HT7 Serotonin Receptors: Weak interaction
α2-Adrenergic Receptors: Agonist
D2 Dopamine Receptors: Weak interaction
L-type Calcium Channels: Inhibitory activity
______